Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# Cobicistat

## Catalog No: tcsc0742

### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

### Specifications

**CAS No:**
1004316-88-4

**Formula:**
$C_{40}H_{53}N_7O_5S_2$

**Pathway:**
Metabolic Enzyme/Protease

**Target:**
Cytochrome P450

**Purity / Grade:**
>98%

**Solubility:**
DMSO : ≥ 29 mg/mL (37.37 mM)

**Alternative Names:**
GS-9350

**Observed Molecular Weight:**
776.02

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

## Product Description

Cobicistat is a potent, and selective inhibitor of **cytochrome P450 3A (CYP3A)** enzymes with **$IC_{50}$** of 30-285 nM.

IC50 & Target: IC50: 30-285 nM (Cytochrome P450)[1]

***In Vitro:*** Cobicistat (GS-9350) is a potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes as a pharmacoenhancer. GS-9350 inhibits CYP3A with $IC_{50}$ spectrum from 30 nM to 285 nM. In contrast to ritonavir, GS-9350 is devoid of anti-HIV activity, with $IC_{50}$ of > 30 μM against HIV-1 protease and $EC_{50}$ of > 30μM in MT-2 HIV infection assay, and is thus more suitable for use in boosting anti-HIV drugs without risking selection of potential drug-resistant HIV variants. GS-9350 shows reduced liability for drug interactions and may have potential improvements in tolerability over ritonavir[1]. Cobicistat is a novel cytochrome P450 3A4 inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition[2].